{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-013167","form_type":"8-K","ticker":"CURX","cik":"0002025942","company_name":"Curanex Pharmaceuticals Inc","filed_at":"2025-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.851576+00:00","generated_at":"2026-05-17T06:47:27.295080+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Curanex Pharma underwriters exercise full over-allotment; additional $2.25M raised","bullets":["Over-allotment option exercised in full; 562,500 shares at $4.00, raising additional $2.25M.","Total IPO gross proceeds: $17.25M from 4,312,500 shares.","Shares outstanding after overallotment: 28,312,500.","Lead underwriter Dominari Securities; co-underwriters Pacific Century and Revere.","Company advances botanical drug Phyto-N for inflammatory diseases, targeting Phase I."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-013167","json":"https://secwatch.observer/filing/0001493152-25-013167.json","markdown":"https://secwatch.observer/filing/0001493152-25-013167.md","text":"https://secwatch.observer/filing/0001493152-25-013167.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2025942/000149315225013167/0001493152-25-013167-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2025942/000149315225013167/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:47:27.295080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}